Tag: cancer care

  • Stakeholders demand increased government investment in Cancer Care

    Stakeholders demand increased government investment in Cancer Care

    Amid Nigeria’s rising cancer burden, stakeholders have called on the Federal and State Governments, as well as private sector players, to intensify investments in advanced cancer technology, medical equipment, and healthcare personnel.

    The call was made during the 10th World Cancer Day Walk, Race, Cycle, Ride, Skate, and Marathon Against Cancer, organized by Project PINK BLUE at Transcorp Hilton, Abuja, to mark World Cancer Day.

    While commending efforts to establish new cancer centers, stakeholders stressed that equipping existing facilities with state-of-the-art diagnostic and treatment tools, improving accessibility to care, and addressing the exodus of medical professionals remain urgent priorities.

    With Nigeria leading sub-Saharan Africa in cancer prevalence—recording 127,763 new cases and 79,542 deaths in 2022—experts warned that the figures have likely risen, making the need for advanced treatment more pressing.

    Gloria Okwu, a breast cancer survivor and Program Coordinator for Project PINK BLUE, emphasized the need for patient-centered care and policy reforms to improve treatment access.

    Speaking on this year’s theme, “United by Unique,” she underscored the importance of tailored medical interventions rather than a one-size-fits-all approach.

    “We urge the government to address the growing brain drain in the medical field. Without doctors, how do we get treated? Our hospitals need proper funding and infrastructure, without these, how do we heal? Patients require access to medicine and psychological support, yet the current system struggles to provide these essentials.

    “We appreciate the government’s efforts, but more needs to be done. As a patient, I see firsthand the challenges, one week, you consult a doctor, and the next, they’ve left the country. Imagine having to wait a month for an appointment when every day counts. If we had enough oncologists, I wouldn’t have to endure such delays, but the few remaining are overwhelmed. They are human, not machines, we can’t expect them to bear an impossible workload.

    “The Cancer Health Fund is a step in the right direction, and we are grateful for the relief it has provided but it only covers three types of cancer. What about patients with other forms? What about children battling cancer? Expanding this fund could be life-changing for so many.

    Read Also: NLCC rededicates to providing quality, affordable cancer care

    “So, while we commend the government’s progress, we urge them to do more. Strengthening the health sector is not an option, it’s a necessity.”

    She further emphasized the importance of early detection through screening, saying, “Our goal is to identify cases early and raise awareness about the importance of screening. That’s why we are here today.

    “Beyond this, we will also engage policymakers, those with the power to drive change. We will present real-time data on the devastating impact of cancer and offer recommendations. The aim is to push for policies that strengthen cancer care and ensure better outcomes for patients.”

    “Essential medical equipment such as PET CT scans, brachytherapy machines, and modern radiotherapy tools, along with precision medicine and targeted therapies, are crucial for improving treatment outcomes.

    “Additionally, strengthening the healthcare workforce by equipping doctors, nurses, pharmacists, and pathologists with the necessary skills and resources is vital for delivering effective care,” he added.

    Okwuoma Chika Dibia, Vice President of the Nigeria Cancer Society, commended the Federal Government for establishing the Cancer Health Fund, which has eased the financial burden on many families.

  • The future of cancer care with medical biotechnology

    The future of cancer care with medical biotechnology

    Cancer remains one of the foremost health challenges worldwide, driven by the cellular transformation that leads to uncontrolled cell proliferation and tumor growth. 

    Conventional treatments often face hurdles such as drug resistance, due to the genetic diversity and adaptive capabilities of tumor cells. 

    Innovative therapies are critically needed to target the intricate molecular pathways involved in cancer development and progression.

    Temitope Israel David, a graduate in Bioinformatics from the Moscow Institute of Physics and Technology, stands at the forefront of this fight. 

    His recent exploration into the potential of non-immunoglobulin synthetic binding proteins (SBPs) for oncology opens new avenues for targeted cancer therapy. 

    These engineered proteins, thanks to their smaller size and enhanced stability, can navigate the complex cellular environment more effectively than traditional antibodies.

    David’s work, particularly on synthetic binding proteins such as monobodies, DARPins, and anticalins, presents significant implications for cancer diagnosis and treatment. 

    Read Also: FCT police arrest gang leader, accomplices over killing of ex-girlfriend

    These SBPs can be engineered to target specific oncoproteins involved in cancer signaling pathways, offering a more precise approach compared to broad-spectrum therapies. 

    This precision not only enhances the efficacy of the treatments but also minimises side effects, paving the way for therapies that are both effective and patient-friendly. 

    Moreover, the adaptability of SBPs to various therapeutic and diagnostic platforms showcases their potential in the development of personalised medicine, fundamentally changing how we approach cancer treatment.

    The implications of Temitope Israel David’s research extend far beyond the laboratory, with potential global impact on cancer care. 

    As cancer remains a leading cause of death worldwide, the need for more effective and accessible treatments is critical, particularly in low and middle-income countries where healthcare resources are often limited. 

    SBPs could offer a cost-effective solution, providing targeted therapies that reduce the need for extensive treatment regimes and minimize hospital stays. 

    This approach aligns with global health objectives aiming to improve cancer survival rates and enhance the quality of life for patients across diverse geographical and economic settings.

    The work of Temitope Israel David represents a significant step forward in the fight against cancer. 

    By harnessing the power of synthetic binding proteins, his research offers a new toolkit for tackling this complex disease with precision and efficacy. 

    As we continue to face the challenges of cancer treatment, the innovative strategies developed by David and his colleagues inspire hope for a future where cancer can be managed more effectively and with greater compassion for patients worldwide. 

    Through continued research, collaboration, and commitment to medical innovation, we are moving closer to turning the tide against cancer, ensuring better outcomes for all those affected.